Association between carcinoembryonic antigen levels and the applied value of 18F‑fluorodeoxyglucose positron emission tomography/computed tomography in post‑operative recurrent and metastatic colorectal cancer

Bu,Wenzhe; Wei,Ran; Li,Jinpeng; Wang,Lijun; Shi,Congcong; Song,Jinlong; Ma,Shuangshuang; Chen,Hua; Cong,Ning

doi:10.3892/ol.2014.2523

Association between carcinoembryonic antigen levels and the applied value of 18F‑fluorodeoxyglucose positron emission tomography/computed tomography in post‑operative recurrent and metastatic colorectal cancer

Authors:
- Wenzhe Bu
- Ran Wei
- Jinpeng Li
- Lijun Wang
- Congcong Shi
- Jinlong Song
- Shuangshuang Ma
- Hua Chen
- Ning Cong
View Affiliations

Affiliations: Department of Surgical Oncology (Interventional Therapy), Shandong Cancer Hospital and Institute, Shandong Academy of Medical Sciences, Jinan, Shandong 250117, P.R. China, Department of Computed Tomography, Shandong Cancer Hospital and Institute, Shandong Academy of Medical Sciences, Jinan, Shandong 250117, P.R. China, Department of Computed Tomography, Shandong Medical Imaging Research Institute, Jinan, Shandong 250000, P.R. China, Six Ward of Shandong Mental Health Center, Jinan, Shandong 250014, P.R. China
Published online on: September 11, 2014 https://doi.org/10.3892/ol.2014.2523
Pages: 2649-2653

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Positron emission tomography (PET) using 18F‑fluorodeoxyglucose has been widely used for analyzing cellular metabolism. The present study aimed to evaluate the association between the diagnostic value of PET/computed tomography (CT) in patients with post‑operative recurrent and metastatic colorectal cancer (CRC), and the different levels of carcinoembryonic antigen (CEA). A total of 105 suspected recurrent and metastatic CRC patients (67 males and 38 females; mean age, 48.5 years) were included in this retrospective study. All the patients underwent PET/CT examination. The differences in the PET/CT diagnostic values of CEA‑positive and ‑negative patients with recurrent CRC following surgery were retrospectively analyzed and compared. Among the 105 CRC patients, 87 exhibited recurrence and metastasis, as confirmed by histopathological diagnosis or clinical follow‑up data. By contrast, the PET/CT examination results revealed that 85 cases were true positives (a false positive foci was diagnosed in one of the patients), 18 were true negatives and 2 were false negatives. Correspondingly, the sensitivity and degree of accuracy were 97.7 and 97.1%, respectively. The detection rates of PET/CT for the recurrence and metastases were 85.3% in the CEA‑positive group and 75.7% in the CEA‑negative group. No significant differences were observed between the two groups. Overall, CEA levels do not help improve the detection rate of PET/CT in the recurrence and metastasis of CRC. PET/CT imaging has a high sensitivity and degree of accuracy in detecting recurrence and metastasis following CRC surgery. Therefore, this method is ideal for monitoring relapsed and metastatic foci of post‑operative colon cancer cases.

View Figures

View References

1	Desch CE, Benson AB III, Somerfield MR, et al; American Society of Clinical Oncology. Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 23:8512–8519. 2005.
2	Elias D, Sideris L, Pocard M, et al: Results of R0 resection for colorectal liver metastases associated with extrahepatic disease. Ann Surg Oncol. 11:274–280. 2004.
3	Lin JK, Lin CC, Yang SH, et al: Early postoperative CEA level is a better prognostic indicator than is preoperative CEA level in predicting prognosis of patients with curable colorectal cancer. Int J Colorectal Dis. 26:1135–1141. 2011.
4	Dirisamer A, Halpern BS, Flöry D, et al: Performance of integrated FDG-PET/contrast-enhanced CT in the staging and restaging of colorectal cancer: comparison with PET and enhanced CT. Eur J Radiol. 73:324–328. 2010.
5	Zhang C, Chen Y, Xue H, et al: Diagnostic value of FDG-PET in recurrent colorectal carcinoma: a meta-analysis. Int J Cancer. 124:167–173. 2009.
6	Zhang Y, Feng B, Zhang GL, et al: Value of ¹⁸F-FDG PET-CT in surveillance of postoperative colorectal cancer patients with various carcinoembryonic antigen concentrations. World J Gastroenterol. 20:6608–6614. 2014.
7	Panagiotidis E, Datseris IE, Rondogianni P, et al: Does CEA and CA 19–9 combined increase the likelihood of 18F-FDG in detecting recurrence in colorectal patients with negative CeCT? Nucl Med Commun. 35:598–605. 2014.
8	Makis W, Kurzencwyg D and Hickeson M: 18F-FDG PET/CT superior to serum CEA in detection of colorectal cancer and its recurrence. Clin Imaging. 37:1094–1097. 2013.
9	Tan E, Gouvas N, Nicholls RJ, et al: Diagnostic precision of carcinoembryonic antigen in the detecetion of recurrence of colorectal cancer. Surg Oncol. 18:15–24. 2009.
10	Ding Q, Cheng X, Yang L, et al: PET/CT evaluation of response to chemotherapy in non-small cell lung cancer: PET response criteria in solid tumors (PERCIST) versus response evaluation criteria in solid tumors (RECIST). J Thorac Dis. 6:677–683. 2014.
11	Litière S, de Vries EG, Seymour L, et al; RECIST Committee. The components of progression as explanatory variables for overall survival in the Response Evaluation Criteria in Solid Tumours 1.1 database. Eur J Cancer. 50:1847–1853. 2014.
12	Esteves FP, Schuster DM and Halkar RK: Gastrointestinal tract malignancies and positron emission tomography: an overview. Semin Nucl Med. 36:169–181. 2006.
13	Nielsen HJ, Jess P, Aldulaymi BH, et al: Early detection of recurrence after curative resection for colorectal cancer - obstacles when using soluble biomarkers? Scand J Gastroenterol. 48:326–333. 2013.
14	Liu FY, Chen JS, Changchien CR, et al: Utility of 2-fluoro-2-deoxy-D-glucose positron emission tomography in managing patients of colorectal cancer with unexplained carcinoembryomic antigen elevation at different levels. Dis Colon Rectum. 48:1900–1912. 2005.
15	Moertel CG, Fleming TR, Macdonald JS, et al: An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA. 270:943–947. 1993.
16	Zerhouni EA, Rutter C, Hamilton SR, et al: CT and MR imaging in the staging of colorectal carcinoma: report of the Radiology Diagnostic Oncology Group II. Radiology. 200:443–451. 1996.
17	Ozkan E, Soydal C, Araz M, et al: The role of 18F-FDG PET/CT in detecting colorectal cancer recurrence in patients with elevated CEA levels. Nucl Med Commun. 33:395–402. 2012.
18	Chiewvit S, Jiranantanakorn T, Apisarnthanarak P, et al: Detection of recurrent colorectal cancer by 18F-FDG PET/CT comparison with contrast enhanced CT scan. J Med Assoc Thai. 96:703–708. 2013.
19	Peng NJ, Hu C, King TM, et al: Detection of resectable recurrences in colorectal cancer patients with 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography. Cancer Biother Radiopharm. 28:479–487. 2013.
20	Lu YY, Chen JH, Chien CR, et al: Use of FDG-PET or PET/CT to detect recurrent colorectal cancer in patients with elevated CEA: a systematic review and meta-analysis. Int J Colorectal Dis. 28:1039–1047. 2013.
21	Lee JE, Kim SW, Kim JS, et al: Prognostic value of 18-fluorodeoxyglucose positron emission tomography-computed tomography in resectable colorectal cancer. World J Gastroenterol. 18:5072–5077. 2012.
22	Choi EK, Yoo IeR, Park HL, et al: Value of Surveillance (18)F-FDG PET/CT in Colorectal Cancer: Comparison with Conventional Imaging Studies. Nucl Med Mol Imaging. 46:189–195. 2012.
23	Sanli Y, Kuyumcu S, Ozkan ZG, et al: The utility of FDG-PET/CT as an effective tool for detecting recurrent colorectal cancer regardless of serum CEA levels. Ann Nucl Med. 26:551–558. 2012.
24	Maas M, Rutten IJ, Nelemans PJ, et al: What is the most accurate whole-body imaging modality for assessment of local and distant recurrent disease in colorectal cancer? A meta-analysis: imaging for recurrent colorectal cancer. Eur J Nucl Med Mol Imaging. 38:1560–1571. 2011.
25	Mittal BR, Senthil R, Kashyap R, et al: 18F-FDG PET-CT in evaluation of postoperative colorectal cancer patients with rising CEA level. Nucl Med Commun. 32:789–793. 2011.
26	Schmidt GP, Baur-Melnyk A, Haug A, et al: Whole-body MRI at 1.5 T and 3 T compared with FDG-PET-CT for the detection of tumor recurrence in patients with colorectal cancer. Eur Radiol. 19:1366–1378. 2009.
27	Simó M, Lomeña F, Setoain J, et al: FDG-PET improves the management of patients with suspected recurrence of colorectal cancer. Nucl Med Commun. 23:975–982. 2002.